Lithium and disease modification: A systematic review and meta-analysis in Alzheimer's and Parkinson's disease
Date
Authors
Singulani, Monique Patricio
Ferreira, Ana Flávia Fernandes
Figueroa, Paulina Sepúlveda
Cuyul-Vásquez, Iván
Talib, Leda Leme
Britto, Luiz Roberto Giorgetti
Forlenza, Orestes Vicente
Ferreira, Ana Flávia Fernandes
Figueroa, Paulina Sepúlveda
Cuyul-Vásquez, Iván
Talib, Leda Leme
Britto, Luiz Roberto Giorgetti
Forlenza, Orestes Vicente
Authors
Date
Datos de publicación:
10.1016/j.arr.2024.102231
Keywords
Alzheimer's Disease - Lithium - Neuroprotection - Parkinson's Disease - Prevention And Treatment - Aluminum Chloride - Amyloid Beta Protein - Dermatan Sulfate - Galactose - Gluconic Acid - Lithium - Lithium Carbonate - Lithium Chloride - Lithium Citrate - Okadaic Acid - Streptozocin - Tyrosine 3 Monooxygenase - Lithium - Lithium Compounds - Neuroprotective Agents - Aluminum Chloride - Amyloid Beta Protein - Amyloid Beta Protein[25-35] - Dermatan Sulfate - Galactose - Gluconic Acid - Immunotoxin - Immunotoxin 192 Immunoglobulin Saporin - Lithium - Lithium Benzoate - Lithium Carbonate - Lithium Chloride - Lithium Citrate - Lithium Pyrroloquinoline - Lithium Salicylate Proline - Neuroprotective Agent - Okadaic Acid - Streptozocin - Tau Protein - Tyrosine 3 Monooxygenase - Unclassified Drug - Lithium Derivative - Aged - Alzheimer Disease - Cochrane Library - Cognition - Embase - Female - Human - Locomotion - Male - Medline - Meta Analysis - Neuroprotection - Nonhuman - Parkinson Disease - Preclinical Study - Preferred Reporting Items For Systematic Reviews And Meta-analyses - Protein Blood Level - Review - Systematic Review - Web Of Science - Animal - Degenerative Disease - Alzheimer Disease - Animals - Humans - Lithium - Lithium Compounds - Neurodegenerative Diseases - Neuroprotective Agents - Parkinson Disease
Collections
Abstract
The role of lithium as a possible therapeutic strategy for neurodegenerative diseases has generated scientific interest. We systematically reviewed and meta-analyzed pre-clinical and clinical studies that evidenced the neuroprotective effects of lithium in Alzheimer's (AD) and Parkinson's disease (PD). We followed the PRISMA guidelines and performed the systematic literature search using PubMed, EMBASE, Web of Science, and Cochrane Library. A total of 32 articles were identified. Twenty-nine studies were performed in animal models and 3 studies were performed on human samples of AD. A total of 17 preclinical studies were included in the meta-analysis. Our analysis showed that lithium treatment has neuroprotective effects in diseases. Lithium treatment reduced amyloid-? and tau levels and significantly improved cognitive behavior in animal models of AD. Lithium increased the tyrosine hydroxylase levels and improved motor behavior in the PD model. Despite fewer clinical studies on these aspects, we evidenced the positive effects of lithium in AD patients. This study lends further support to the idea of lithium's therapeutic potential in neurodegenerative diseases. © 2024 Elsevier B.V., All rights reserved.
Description
Keywords
Alzheimer's Disease , Lithium , Neuroprotection , Parkinson's Disease , Prevention And Treatment , Aluminum Chloride , Amyloid Beta Protein , Dermatan Sulfate , Galactose , Gluconic Acid , Lithium , Lithium Carbonate , Lithium Chloride , Lithium Citrate , Okadaic Acid , Streptozocin , Tyrosine 3 Monooxygenase , Lithium , Lithium Compounds , Neuroprotective Agents , Aluminum Chloride , Amyloid Beta Protein , Amyloid Beta Protein[25-35] , Dermatan Sulfate , Galactose , Gluconic Acid , Immunotoxin , Immunotoxin 192 Immunoglobulin Saporin , Lithium , Lithium Benzoate , Lithium Carbonate , Lithium Chloride , Lithium Citrate , Lithium Pyrroloquinoline , Lithium Salicylate Proline , Neuroprotective Agent , Okadaic Acid , Streptozocin , Tau Protein , Tyrosine 3 Monooxygenase , Unclassified Drug , Lithium Derivative , Aged , Alzheimer Disease , Cochrane Library , Cognition , Embase , Female , Human , Locomotion , Male , Medline , Meta Analysis , Neuroprotection , Nonhuman , Parkinson Disease , Preclinical Study , Preferred Reporting Items For Systematic Reviews And Meta-analyses , Protein Blood Level , Review , Systematic Review , Web Of Science , Animal , Degenerative Disease , Alzheimer Disease , Animals , Humans , Lithium , Lithium Compounds , Neurodegenerative Diseases , Neuroprotective Agents , Parkinson Disease
Citation
10.1016/j.arr.2024.102231